## Clinical Scenario Analysis This patient has **smear-positive pulmonary tuberculosis** with classic radiological findings (cavitary disease in upper lobe). The diagnosis is confirmed by AFB positivity on sputum smear microscopy. ## Key Point: **In a smear-positive TB patient with clinical and radiological evidence of active disease, anti-tuberculous therapy should be initiated immediately without waiting for culture or DST results.** Delay in treatment increases transmission risk and worsens patient outcomes. ## High-Yield: According to WHO and Indian TB guidelines (NTEP), the standard first-line regimen is: - **Intensive phase (2 months):** HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol) - **Continuation phase (4 months):** HR (Isoniazid, Rifampicin) - **Total duration:** 6 months for drug-susceptible TB ## Clinical Pearl: Smear-positive patients are **infectious** and pose a public health risk. Initiating therapy promptly: 1. Reduces transmission within 2 weeks of starting treatment 2. Prevents progression to severe disease 3. Reduces mortality 4. Culture and DST are confirmatory and guide therapy modification if drug resistance is detected, but should NOT delay initiation of standard therapy ## Diagnostic Confirmation Hierarchy | Finding | Diagnostic Value | Action | |---------|------------------|--------| | AFB smear positive | Confirms active TB (infectious) | **Start therapy immediately** | | Clinical + CXR + AFB+ | Presumptive TB confirmed | **Do not wait for culture** | | Culture positive | Gold standard (takes 2–8 weeks) | Confirmatory; guides DST | | DST results | Detects drug resistance | Modifies regimen if MDR/XDR | ## Why TST is Not the Next Step **TST is a diagnostic test for TB infection, not active disease.** In a smear-positive patient, TST is redundant and delays therapy initiation.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.